SCHEDULE 13G/A: Marshall Wace Discloses 9.99% Stake in InspireMD

Investment manager Marshall Wace LLP has reported a 9.99% beneficial ownership stake in InspireMD, Inc., including shares from warrants subject to a regulatory blocker.

Summary

• Marshall Wace LLP, a UK-based investment manager, has filed an amendment to its Schedule 13G, disclosing its beneficial ownership in InspireMD, Inc.
• The filing indicates a potential beneficial ownership of 28,103,699 shares of InspireMD, Inc. Common Stock, which includes 26,243,294 shares issuable upon the full exercise of warrants.
• However, due to a 9.99% blocker, Marshall Wace LLP's actual beneficial ownership is capped at 9.99% of the outstanding Common Stock.
• This 9.99% is calculated based on 41,720,662 shares outstanding as of August 4, 2025, meaning the actual number of shares beneficially owned, after applying the blocker, is approximately 4,167,893 shares.
• The shares are held in the ordinary course of business and not for the purpose of changing or influencing control of InspireMD, Inc.
• MW XO Health Innovations Fund LP, one of the MW Funds managed by Marshall Wace, has the right to receive dividends or proceeds from the sale of more than 5% of the outstanding Common Stock.

Sentiment

Score: 6

Explanation: While the presence of a major institutional investor like Marshall Wace LLP holding a significant stake is generally positive, the substantial difference between potential and actual beneficial ownership due to the 9.99% blocker introduces a notable limitation. This cap on full warrant exercise and direct equity ownership slightly dampens the overall positive sentiment, as the full extent of their investment is not immediately realized in common stock.

Positives

• A significant institutional investor, Marshall Wace LLP, holds a substantial potential stake (28,103,699 shares, including warrants) in InspireMD, Inc., indicating strong interest.
• The holding includes a large number of warrants (26,243,294 shares), representing a long-term commitment and potential future equity conversion.
• Marshall Wace LLP maintains its actual beneficial ownership at the maximum allowed 9.99% of the class, signaling continued confidence within regulatory limits.

Negatives

• The 9.99% blocker significantly limits Marshall Wace LLP's ability to fully exercise its warrants, meaning a large portion of the potential shares (26,243,294 warrants) cannot be converted into common stock if it exceeds the 9.99% threshold.
• The discrepancy between the reported potential beneficial ownership (28,103,699 shares) and the actual beneficial ownership (approx. 4,167,893 shares due to the blocker) could lead to investor confusion regarding the true extent of the stake.

Risks

• The 9.99% blocker on warrant exercise means Marshall Wace LLP cannot fully realize its potential ownership from warrants if it would push their stake above this threshold, limiting their ability to increase their direct equity position.
• Changes in InspireMD, Inc.'s outstanding share count could alter the actual number of shares Marshall Wace LLP can beneficially own while adhering to the 9.99% blocker.
• The inability to fully exercise warrants might limit Marshall Wace LLP's influence or voting power compared to what their full warrant holdings would otherwise imply.

Future Outlook

The filing does not provide a future outlook for InspireMD, Inc. from the company itself. Marshall Wace LLP certifies that its holdings are for ordinary course of business and not for control.

Industry Context

A significant stake by a prominent investment manager like Marshall Wace LLP in a company like InspireMD, Inc. (likely in the medical device or biotechnology sector, given its name) can signal institutional confidence in the company's technology, market position, or future growth prospects. Such disclosures are closely watched by the market as they can influence investor sentiment and potentially attract further institutional interest.

Related Party Transactions

• MW XO Health Innovations Fund LP, a fund managed by Marshall Wace LLP, has the right to receive dividends or proceeds from the sale of more than 5% of InspireMD, Inc.'s outstanding Common Stock.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding a near-10% stake could increase confidence and potentially attract other investors, positively impacting share price.
• Company Management: A large institutional holder may exert influence through engagement, even if not seeking control, potentially impacting strategic decisions.

Key Dates

Recommendation

The filing confirms Marshall Wace LLP's continued significant interest in InspireMD, Inc., maintaining a 9.99% beneficial ownership stake, which includes a substantial number of warrants. This institutional backing is a positive signal. However, the 9.99% blocker prevents the full exercise of these warrants, limiting the immediate increase in Marshall Wace's direct equity position. The filing primarily concerns ownership disclosure and does not provide new operational or financial performance data for InspireMD, Inc. Therefore, a 'hold' recommendation is appropriate, acknowledging the institutional confidence while recognizing the structural limitations on the investor's stake.

Keywords

InspireMD Inc., Marshall Wace LLP, Schedule 13G, Beneficial Ownership, Warrants, Institutional Investor, Medical Devices, Cardiovascular, SEC Filing